ERA - Leading European Nephrology

My ERA Join ERA

Home | Video pages | Webcast | Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease

Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease

Share

https://www.youtube.com/watch?v=HhkmSyQ7uWU copy

Access paper

Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial

Other e-seminars from this series

SGLT2 inhibition for patients with ADPKD – closing the evidence

ERA Journal Club

Potential and pitfalls of measuring circulating anti-nephrin autoantibodies in glomerular diseases

ERA Journal Club

Disease-modifying anti-nephropathic drugs (DMANDs) – A definition proposed by the IWG of ERA

ERA Journal Club

Digital physical activity intervention via the Kidney BEAM platform in patients with polycystic kidney disease

ERA Journal Club

Aldosterone synthase inhibitors in CKD (and EASi-KIDNEY’s outline design)

ERA Journal Club

Epidemiological and clinicopathological characteristics of vascular-limited renal AL amyloidosis

ERA Journal Club

Kidney Transplantation in Patients with Polycystic Kidney Disease

ERA Journal Club

Post-transplant renal anaemia: a call to action from a national study in routine clinical practice

ERA Journal Club

Low dialysate sodium and 48-h ambulatory blood pressure in patients with intradialytic hypertension

ERA Journal Club

Using Artificial Intelligence to Predict Mortality in AKI Patients: A systematic review/Meta-Analysis

ERA Journal Club

Clinical impact of the Kidney Failure Risk Equation for vascular access planning

ERA Journal Club

Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies

ERA Journal Club